Scorpion Therapeutics
Scorpion Therapeutics is a private biotechnology company developing small molecule precision oncology therapies.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Scorpion Therapeutics, Inc. is a private biotechnology company developing small molecule precision oncology therapies. Its PI3Kα inhibitor program STX-478, a once-daily oral, mutant-selective PI3Kα inhibitor, is being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. In January 2025, Eli Lilly and Company announced a definitive agreement to acquire Scorpion's PI3Kα inhibitor program STX-478.
History
Scorpion Therapeutics, Inc. is a private biotechnology company developing small molecule precision oncology therapies. Its STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. On January 13, 2025, Eli Lilly and Company and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478.
Products and positioning
Private biotechnology company developing small molecule precision oncology therapies.
STX-478
A once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.
Recent events
Scorpion Therapeutics debuts with $108 million in funding[3]
Reported:
Scorpion Therapeutics debuted with $108 million in funding from Atlas Venture, Omega Funds, Vida Venture, Abingworth and Partners HealthCare Innovation to pursue its precision-oncology approach.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/scorpion-therapeutics-united-states · Editorial policy · How profiles are compiled